Product Description
For corneal disease (dry eye) (Sourced from: https://www.santen.com/en/assets/pdf/ir/document/mtg2011to2013.pdf)
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Santen
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Keratoconjunctivitis Sicca|Dry Eye Disease|Dry Eye Syndromes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01239069 | P2 |
Completed |
Keratoconjunctivitis Sicca|Dry Eye Disease|Dry Eye Syndromes |
2011-10-01 |